Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. List of Illustrations - p. iii 8. List of Tables - p. iii 9. Section I: Lung Cancer Control and Epidemiology - p. iii 10. Chapter 1: Classic Epidemiology of Lung Cancer - p. iii 11. Chapter 2: Tobacco Control and Primary Prevention - p. g7 12. Chapter 3: Assessing and Treating Tobacco Use in Lung Cancer Care - p. g17 13. Chapter 4: Lung Cancer in Never-Smokers: A Different Disease - p. g22 14. Chapter 5: Gender-Related Differences in Lung Cancer - p. g28 15. Chapter 6: Genetic Susceptibility to Lung Cancer - p. g45 16. Chapter 7: Screening for Lung Cancer - p. g51 17. Chapter 8: Preclinical Biomarkers for the Early Detection of Lung Cancer - p. g58 18. Chapter 9: Chemoprevention of Lung Cancer and Management of Early Lung Cancer - p. g68 19. Section II: Lung Cancer Molecular Carcinogenesis - p. g80 20. Chapter 10: Copy Number Abnormalities and Gene Fusions in Lung Cancer: Present and Developing Technologies - p. g80 21. Chapter 11: Mutational Events in Lung Cancer: Present and Developing Technologies - p. g93 22. Chapter 12: Epigenetic Events in Lung Cancer: Chromatin Remodeling and DNA Methylation - p. g103 23. Chapter 13: Stem Cells and Lung Cancer: In Vitro and In Vivo Studies - p. g116 24. Chapter 14: Microenvironment and Lung Cancer - p. g120 25. Chapter 15: MicroRNAs as Biomarkers for Lung Cancer - p. g127 26. Section III: Immunology - p. g136 27. Chapter 16: Humoral and Cellular Immune Dysregulation and Lung Cancer - p. g136 28. Section IV: Pathology - p. g142 29. Chapter 17: Classic Anatomic Pathology and Lung Cancer - p. g142 30. Chapter 18: Molecular Testing in Lung Cancer - p. g162 31. Chapter 19: Management of Small Histologic and Cytologic Specimens in the Molecular Era - p. g176 32. Section V: Clinical and Radiologic Presentation of Lung Cancer - p. g185 33. Chapter 20: Clinical Presentation and Prognostic Factors in Lung Cancer - p. g185 34. Chapter 21: Conventional Imaging of Lung Cancer - p. g197 35. Chapter 22: Positron Emission Tomography Imaging of Lung Cancer - p. g218 36. Section VI: Diagnosis and Staging of Lung Cancer - p. g232 37. Chapter 23: Diagnostic Workup for Suspected Lung Cancer Confined to the Chest - p. g232 38. Chapter 24: Preoperative and Intraoperative Invasive Staging of the Mediastinum - p. g239 39. Chapter 25: The Eighth Edition of the Tumor, Node, and Metastasis Classification of Lung Cancer - p. g252 40. Section VII: Surgical Management of Lung Cancer - p. g264 41. Chapter 26: Preoperative Functional Evaluation of the Surgical Candidate - p. g264 42. Chapter 27: Results of Video-Assisted Techniques for Resection of Lung Cancer - p. g272 43. Chapter 28: Robotic Surgery: Techniques and Results for Resection of Lung Cancer - p. g281 44. Chapter 29: Extent of Surgical Resection for Stage I and II Lung Cancer - p. g287 45. Chapter 30: Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors - p. g294 46. Chapter 31: Extended Resections for Lung Cancer: Bronchovascular Sleeve Resections - p. g303 47. Chapter 32: Multiple Nodules: Management of Synchronous and Metachronous Lung Cancers - p. g307 48. Chapter 33: Surgical Management of Patients Considered Marginally Resectable - p. g313 49. Section VIII: Radiotherapeutic Management of Lung Cancer - p. g317 50. Chapter 34: Technical Requirements for Lung Cancer Radiotherapy - p. g317 51. Chapter 35: Radiobiology of Lung Cancer - p. g328 52. Chapter 36: Patient Selection for Radiotherapy - p. g336 53. Chapter 37: Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease - p. g341 54. Chapter 38: Ablation Options for Localized Nonsmall Cell Lung Cancer - p. g353 55. Chapter 39: Radiotherapy for Locally Advanced Nonsmall Cell Lung Cancer Including Combined Modality - p. g362 56. Chapter 40: Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation - p. g373 57. Chapter 41: Palliative Radiotherapy for Lung Cancer - p. g381 58. Chapter 42: Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, and Heart - p. g392 59. Chapter 43: Neurotoxicity Related to Radiotherapy and Chemotherapy for Nonsmall Cell and Small Cell Lung Cancer - p. g408 60. Section IX: Chemotherapy and Targeted Agents for Lung Cancer - p. g417 61. Chapter 44: Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer - p. g417 62. Chapter 45: Systemic Options for Second-Line Therapy and Beyond - p. g432 63. Chapter 46: Maintenance Chemotherapy for Nonsmall Cell Lung Cancer - p. g446 64. Chapter 47: Pharmacogenomics in Lung Cancer: Predictive Biomarkers for Chemotherapy - p. g465 65. Chapter 48: New Targets for Therapy in Lung Cancer - p. g478 66. Chapter 49: Management of Toxicities of Targeted Therapies - p. g489 67. Chapter 50: Immunotherapy and Lung Cancer - p. g500 68. Chapter 51: Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer - p. g510 69. Chapter 52: Treatment of Extensive-Stage Small Cell Lung Cancer - p. g524 70. Section X: Other Thoracic Malignancies - p. g535 71. Chapter 53: Malignant Mesothelioma - p. g535 72. Chapter 54: Mediastinal Tumors - p. g549 73. Chapter 55: Neuroendocrine Tumors of the Lung Other Than Small Cell Lung Cancer - p. g554 74. Chapter 56: Thymic Tumors - p. g568 75. Section XI: Symptom Management and Complications - p. g589 76. Chapter 57: Lung Cancer Emergencies - p. g589 77. Chapter 58: The Role of Palliative Care in Lung Cancer - p. g607 78. Section XII: Clinical Trials - p. g619 79. Chapter 59: Clinical Trial Methodology in Lung Cancer: Study Design and End-Point Considerations - p. g619 80. Chapter 60: How to Promote and Organize Clinical Research in Lung Cancer - p. g627 81. Section XIII: Thoracic Oncology Advocacy - p. g634 82. Chapter 61: The Role of Advocacy Groups in Lung Cancer - p. g634 83. Chapter 62: The Role of Health Services Research in Improving the Outcomes for Patients With Lung Cancer - p. g638 84. Appendix - p. g649 85. Diagnostic Algorithms - p. g649 86. Index - p. g657
No hay muestra disponible
No hay ficha técnica disponible
Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. List of Illustrations - p. iii 8. List of Tables - p. iii 9. Section I: Lung Cancer Control and Epidemiology - p. iii 10. Chapter 1: Classic Epidemiology of Lung Cancer - p. iii 11. Chapter 2: Tobacco Control and Primary Prevention - p. g7 12. Chapter 3: Assessing and Treating Tobacco Use in Lung Cancer Care - p. g17 13. Chapter 4: Lung Cancer in Never-Smokers: A Different Disease - p. g22 14. Chapter 5: Gender-Related Differences in Lung Cancer - p. g28 15. Chapter 6: Genetic Susceptibility to Lung Cancer - p. g45 16. Chapter 7: Screening for Lung Cancer - p. g51 17. Chapter 8: Preclinical Biomarkers for the Early Detection of Lung Cancer - p. g58 18. Chapter 9: Chemoprevention of Lung Cancer and Management of Early Lung Cancer - p. g68 19. Section II: Lung Cancer Molecular Carcinogenesis - p. g80 20. Chapter 10: Copy Number Abnormalities and Gene Fusions in Lung Cancer: Present and Developing Technologies - p. g80 21. Chapter 11: Mutational Events in Lung Cancer: Present and Developing Technologies - p. g93 22. Chapter 12: Epigenetic Events in Lung Cancer: Chromatin Remodeling and DNA Methylation - p. g103 23. Chapter 13: Stem Cells and Lung Cancer: In Vitro and In Vivo Studies - p. g116 24. Chapter 14: Microenvironment and Lung Cancer - p. g120 25. Chapter 15: MicroRNAs as Biomarkers for Lung Cancer - p. g127 26. Section III: Immunology - p. g136 27. Chapter 16: Humoral and Cellular Immune Dysregulation and Lung Cancer - p. g136 28. Section IV: Pathology - p. g142 29. Chapter 17: Classic Anatomic Pathology and Lung Cancer - p. g142 30. Chapter 18: Molecular Testing in Lung Cancer - p. g162 31. Chapter 19: Management of Small Histologic and Cytologic Specimens in the Molecular Era - p. g176 32. Section V: Clinical and Radiologic Presentation of Lung Cancer - p. g185 33. Chapter 20: Clinical Presentation and Prognostic Factors in Lung Cancer - p. g185 34. Chapter 21: Conventional Imaging of Lung Cancer - p. g197 35. Chapter 22: Positron Emission Tomography Imaging of Lung Cancer - p. g218 36. Section VI: Diagnosis and Staging of Lung Cancer - p. g232 37. Chapter 23: Diagnostic Workup for Suspected Lung Cancer Confined to the Chest - p. g232 38. Chapter 24: Preoperative and Intraoperative Invasive Staging of the Mediastinum - p. g239 39. Chapter 25: The Eighth Edition of the Tumor, Node, and Metastasis Classification of Lung Cancer - p. g252 40. Section VII: Surgical Management of Lung Cancer - p. g264 41. Chapter 26: Preoperative Functional Evaluation of the Surgical Candidate - p. g264 42. Chapter 27: Results of Video-Assisted Techniques for Resection of Lung Cancer - p. g272 43. Chapter 28: Robotic Surgery: Techniques and Results for Resection of Lung Cancer - p. g281 44. Chapter 29: Extent of Surgical Resection for Stage I and II Lung Cancer - p. g287 45. Chapter 30: Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors - p. g294 46. Chapter 31: Extended Resections for Lung Cancer: Bronchovascular Sleeve Resections - p. g303 47. Chapter 32: Multiple Nodules: Management of Synchronous and Metachronous Lung Cancers - p. g307 48. Chapter 33: Surgical Management of Patients Considered Marginally Resectable - p. g313 49. Section VIII: Radiotherapeutic Management of Lung Cancer - p. g317 50. Chapter 34: Technical Requirements for Lung Cancer Radiotherapy - p. g317 51. Chapter 35: Radiobiology of Lung Cancer - p. g328 52. Chapter 36: Patient Selection for Radiotherapy - p. g336 53. Chapter 37: Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease - p. g341 54. Chapter 38: Ablation Options for Localized Nonsmall Cell Lung Cancer - p. g353 55. Chapter 39: Radiotherapy for Locally Advanced Nonsmall Cell Lung Cancer Including Combined Modality - p. g362 56. Chapter 40: Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation - p. g373 57. Chapter 41: Palliative Radiotherapy for Lung Cancer - p. g381 58. Chapter 42: Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, and Heart - p. g392 59. Chapter 43: Neurotoxicity Related to Radiotherapy and Chemotherapy for Nonsmall Cell and Small Cell Lung Cancer - p. g408 60. Section IX: Chemotherapy and Targeted Agents for Lung Cancer - p. g417 61. Chapter 44: Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer - p. g417 62. Chapter 45: Systemic Options for Second-Line Therapy and Beyond - p. g432 63. Chapter 46: Maintenance Chemotherapy for Nonsmall Cell Lung Cancer - p. g446 64. Chapter 47: Pharmacogenomics in Lung Cancer: Predictive Biomarkers for Chemotherapy - p. g465 65. Chapter 48: New Targets for Therapy in Lung Cancer - p. g478 66. Chapter 49: Management of Toxicities of Targeted Therapies - p. g489 67. Chapter 50: Immunotherapy and Lung Cancer - p. g500 68. Chapter 51: Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer - p. g510 69. Chapter 52: Treatment of Extensive-Stage Small Cell Lung Cancer - p. g524 70. Section X: Other Thoracic Malignancies - p. g535 71. Chapter 53: Malignant Mesothelioma - p. g535 72. Chapter 54: Mediastinal Tumors - p. g549 73. Chapter 55: Neuroendocrine Tumors of the Lung Other Than Small Cell Lung Cancer - p. g554 74. Chapter 56: Thymic Tumors - p. g568 75. Section XI: Symptom Management and Complications - p. g589 76. Chapter 57: Lung Cancer Emergencies - p. g589 77. Chapter 58: The Role of Palliative Care in Lung Cancer - p. g607 78. Section XII: Clinical Trials - p. g619 79. Chapter 59: Clinical Trial Methodology in Lung Cancer: Study Design and End-Point Considerations - p. g619 80. Chapter 60: How to Promote and Organize Clinical Research in Lung Cancer - p. g627 81. Section XIII: Thoracic Oncology Advocacy - p. g634 82. Chapter 61: The Role of Advocacy Groups in Lung Cancer - p. g634 83. Chapter 62: The Role of Health Services Research in Improving the Outcomes for Patients With Lung Cancer - p. g638 84. Appendix - p. g649 85. Diagnostic Algorithms - p. g649 86. Index - p. g657
No hay muestra disponible
No hay ficha técnica disponible